journal article·2019-10-01Open access

Cell-Penetrating Peptides as a Tool for the Cellular Uptake of a Genetically Modified Nitroreductase for use in Directed Enzyme Prodrug Therapy

Simon D. Anderson, Robert J. Hobbs, Vanessa V. Gwenin, Patrick Ball, Lindsey A. Bennie, Jonathan A. Coulter, Chris D. Gwenin

Abstract

Directed enzyme prodrug therapy (DEPT) involves the delivery of a prodrug-activating enzyme to a solid tumour site, followed by the subsequent activation of an administered prodrug. One of the most studied enzyme–prodrug combinations is the nitroreductase from Escherichia coli (NfnB) with the prodrug CB1954 [5-(aziridin-1-yl)-2,4-dinitro-benzamide]. One of the major issues faced by DEPT is the ability to successfully internalize the enzyme into the target cells. NfnB has previously been genetically modified to contain cysteine residues (NfnB-Cys) which bind to gold nanoparticles for a novel DEPT therapy called magnetic nanoparticle directed enzyme prodrug therapy (MNDEPT). One cellular internalisation method is the use of cell-penetrating peptides (CPPs), which aid cellular internalization of cargo. Here the cell-penetrating peptides: HR9 and Pep-1 were tested for their ability to conjugate with NfnB-Cys. The conjugates were further tested for their potential use in MNDEPT, as well as conjugating with the delivery vector intended for use in MNDEPT and tested for the vectors capability to penetrate into cells.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Cancer Research and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Natural Sciences, Bangor University, Bangor, Gwynedd, Wales LL57 2DG, UK

School of Pharmacy, Queen’s University Belfast, Belfast BT7 1NN, UK

References (60)

Show source-provided references
1. Engineering rna for targeted sirna delivery and medical application10.1016/j.addr.2010.03.008 ↗
3. Membrane dynamics and the biogenesis of lysosomes10.1080/0968768031000089546 ↗
5. Cell-penetrating peptides-mechanisms of cellular uptake and generation of delivery systems10.3390/ph3040961 ↗
6. Mechanisms of cellular uptake of cell-penetrating peptides10.1155/2011/414729 ↗
7. Langel, Ü. (2006). Handbook of Cell Penetrating Peptides, Taylor & Francis Group, LLC. [2nd ed.].10.1201/9781420006087 ↗
8. Role of Membrane Potential and Hydrogen Bonding in the Mechanism of Translocation of Guanidinium-Rich Peptides into Cells10.1021/ja0482536 ↗
9. Polyarginine enters cells more efficiently than other polycationic homopolymers10.1034/j.1399-3011.2000.00723.x ↗
10. Cell-penetrating peptides-A brief introduction10.1016/j.bbamem.2006.02.012 ↗
11. Plasmid DNA delivery by arginine-rich cell-penetrating peptides containing unnatural amino acids10.1016/j.bmc.2016.04.031 ↗
12. Topical Delivery of Protein and Peptide Using Novel Cell Penetrating Peptide IMT-P810.1038/srep26278 ↗
13. Cell-penetrating peptide-conjugated lipid nanoparticles for siRNA delivery10.1016/j.bbrc.2014.01.107 ↗
14. Colloidal gold modified with a genetically engineered nitroreductase: Toward a novel enzyme delivery system for cancer prodrug therapy10.1021/la202951p ↗
15. Gene-Directed Enzyme Prodrug Therapy10.1208/s12248-014-9675-7 ↗
16. The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT)10.1007/BF00689810 ↗
17. Nitroreductase gene-directed enzyme prodrug therapy: Insights and advances toward clinical utility10.1042/BJ20150650 ↗
18. Kinetic and Structural Characterisation of Escherichia coli Nitroreductase Mutants Showing Improved Efficacy for the Prodrug Substrate CB195410.1016/j.jmb.2007.02.012 ↗
19. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase10.1016/0006-2952(92)90672-6 ↗
20. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT10.1038/sj.bjc.6601612 ↗
21. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB198410.1038/mt.2009.80 ↗
22. Viral vectors for gene-directed enzyme prodrug therapy10.2174/156652306779010679 ↗
23. Virus-directed enzyme prodrug therapy: Intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer10.1200/JCO.2004.10.005 ↗
24. Valentino, S., Borchardt, R., Hageman, M., Oliyai, R., Maag, H., and Jefferson, T.W. (2005). Antibody-Directed Enzyme Prodrug Therapy Professor. Prodrugs: Challenges and rewards, Springer.
25. Peptide-mediated gene delivery: Influence of peptide structure on gene expression10.1021/bc960079q ↗
26. Gene Transfer with Synthetic Cationic Amphiphiles: Prospects for Gene Therapy10.1021/bc00029a002 ↗
27. Gwenin, V.V., Gwenin, C.D., and Kalaji, M. (2009). Drug Activation Carrier. (EP2473197-A2), European Union Patent.
28. The orientationally controlled assembly of genetically modified enzymes in an amperometric biosensor10.1016/j.bios.2006.12.012 ↗
29. Time dependent HPLC analysis of the product ratio of enzymatically reduced prodrug CB1954 by a modified and immobilised nitroreductase10.1016/j.ejps.2018.11.001 ↗
30. Delivery of Nucleic Acids, Proteins, and Nanoparticles by Arginine-Rich Cell-Penetrating Peptides in Rotifers10.1007/s10126-013-9509-0 ↗
31. Insight into the Mechanism of Internalization of the Cell-Penetrating Carrier Peptide Pep-1 through Conformational Analysis10.1021/bi035682s ↗
32. Intracellular Delivery of Proteins into Mouse Muller Glia Cells in vitro and in vivo Using Pep-1 Transfection Reagent
33. A non-covalent peptide-based strategy for protein and peptide nucleic acid transduction10.1016/j.bbamem.2006.02.006 ↗
34. Delivery and visualization of proteins conjugated to quantum dots in cardiac myocytes10.1016/j.yjmcc.2008.08.006 ↗
35. PEP and CADY-mediated delivery of fluorescent peptides and proteins into living cells10.1016/j.bbamem.2010.02.027 ↗
36. Intracellular delivery of quantum dots mediated by a histidine- and arginine-rich HR9 cell-penetrating peptide through the direct membrane translocation mechanism10.1016/j.biomaterials.2011.01.041 ↗
37. Arginine-rich cell-penetrating peptides deliver gene into living human cells10.1016/j.gene.2012.05.053 ↗
38. Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel multifunctional drug-delivery systems10.1016/j.jconrel.2016.03.020 ↗
39. Identification of novel nitroreductases from Bacillus cereus and their interaction with the CB1954 prodrug10.1016/j.bcp.2015.09.013 ↗
40. Catechols and quercetin reduce MTT through iron ions: A possible artefact in cell viability assays10.1002/ptr.2650090816 ↗
41. The noncellular reduction of MTT tetrazolium salt by TiO2 nanoparticles and its implications for cytotoxicity assays10.1016/j.tiv.2013.03.006 ↗
42. A peptide carrier for the delivery of biologically active proteins into mammalian cells10.1038/nbt1201-1173 ↗
43. A non-covalent peptide-based carrier for in vivo delivery of DNA mimics10.1093/nar/gkm053 ↗
44. Cell-penetrating peptides: From molecular mechanisms to therapeutics10.1042/BC20070116 ↗
45. Native Polyacrylamide Gels
46. Cellular internalization of quantum dots noncovalently conjugated with arginine-rich cell-penetrating peptides10.1166/jnn.2010.2637 ↗
47. Hormesis defined10.1016/j.arr.2007.08.007 ↗
48. Breaking in and busting out: Cell-penetrating peptides and the endosomal escape problem10.1515/bmc-2017-0023 ↗
49. (2019, September 01). Bio-Rad Buffer Formulations. Available online: http://www.bio-rad.com/webroot/web/pdf/lsr/literature/Bulletin_6199.pdf.
50. coli NfsA: An alternative nitroreductase for prodrug activation gene therapy in combination with CB195410.1038/sj.bjc.6605094 ↗
51. Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase i to improve activation of the anticancer prodrug CB195410.1016/j.bcp.2012.07.002 ↗
52. UvrB gene deletion enhances SOS chromotest sensitivity for nitroreductases that preferentially generate the 4-hydroxylamine metabolite of the anti-cancer prodrug CB195410.1016/j.jbiotec.2010.08.007 ↗
53. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB195410.1016/j.bcp.2009.10.008 ↗
54. Development of Gold Coated Superparamagnetic Iron Oxide Nanoparticles for Nitroreductase Delivery10.1149/1.3583517 ↗
55. Determination of Size and Concentration of Gold Nanoparticles from UV—Vis Spectra Determination of Size and Concentration of Gold Nanoparticles from UV—Vis Spectra10.1021/ac0702084 ↗
56. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody10.1016/j.jconrel.2007.03.012 ↗
57. Light-Regulated Release of DNA and Its Delivery to Nuclei by Means of Photolabile Gold Nanoparticles **10.1002/anie.200600214 ↗
58. Nuclear penetration of surface functionalized gold nanoparticles10.1016/j.taap.2009.03.009 ↗
59. Cation surface modification of gold nanoparticles for enhanced cellular uptake and X-Ray radiation therapy10.1039/C5TB00766F ↗
60. Cellular uptake and toxicity of gold nanoparticles in prostate cancer cells: A comparative study of rods and spheres10.1002/jat.1486 ↗